2,10-dihydroxy-12-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-12,13-dihydrofuro[3,4-c]indolo[2,3-a]carbazole-5,7-dione | 174402-49-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2,10-dihydroxy-12-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-12,13-dihydrofuro[3,4-c]indolo[2,3-a]carbazole-5,7-dione
• CAS: 174402-49-4
• 化学式: C₂₆H₂₀N₂O₁₀
• 分子量: 520.452
• InChiKey: XLRPGYLVGCKIIL-YIBMJBSNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.12
• 重原子数：
  38.0
• 可旋转键数：
  2.0
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  194.7
• 氢给体数：
  7.0
• 氢受体数：
  11.0

反应信息

• 作为反应物：
  描述：

  2,10-dihydroxy-12-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-12,13-dihydrofuro[3,4-c]indolo[2,3-a]carbazole-5,7-dione 生成
  参考文献：
  名称：

  新型吲哚咔唑拓扑异构酶I抑制剂的水解机理。

  摘要：

  研究了抗肿瘤剂1在水溶液中的降解动力学和反应产物分布。1的酰亚胺侧挂环的水解是水溶液中热降解的主要方式，pH值1呈V形，表明酰亚胺环的水解可以被酸或碱催化。逐步将1水解为酸酐衍生物3或二羧酸衍生物4，并且在碱性条件下观察到通过初始水解作用形成的中间体2a和2b。已经提出了在水溶液中水解1的整体机理。

  DOI：

  10.1016/j.ejps.2009.12.001
• 作为产物：
  描述：

  13-(β-D-glucopyranosyl)-6-N-methylarcyriaflavin C 在 potassium hydroxide 作用下， 以 水 为溶剂， 生成 2,10-dihydroxy-12-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-12,13-dihydrofuro[3,4-c]indolo[2,3-a]carbazole-5,7-dione
  参考文献：
  名称：

  酰亚胺部分修饰的雷贝卡霉素类似物的合成和生物学评价

  摘要：

  与抗生素瑞贝卡霉素相关的糖基化吲哚并咔唑代表了一类重要的抗肿瘤药物。在我们的结构-活性关系研究过程中，合成了在酰亚胺部分修饰的新的瑞贝卡霉素类似物。在三种人类癌细胞系A2780（卵巢癌），H460（肺癌）和GLC4（小细胞肺癌）中评估了化合物的抗增殖活性。化合物2和4的体外细胞毒性分别以与酰亚胺部分相连的1,3-二氧戊环和（1,3-二氧杂环-4-基）亚甲基为特征，高于参考化合物依地卡林。还研究了化合物2在A2780异种移植模型中诱导肿瘤消退的作用。

  DOI：

  10.1016/j.bmcl.2012.06.016

文献信息

• Synthesis and biological activities of NB-506 analogues modified at the glucose group
  作者：Mitsuru Ohkubo、Teruyuki Nishimura、Hiroshi Kawamoto、Masato Nakano、Teruki Honma、Tomoko Yoshinari、Hiroharu Arakawa、Hiroyuki Suda、Hajime Morishima、Susumu Nishimura

  DOI：10.1016/s0960-894x(00)00004-4

  日期：2000.3

  A new indolocarbazole compound, NB-506 (1), modified at the glucose group yielded a beta-D-glucopyranoside, J-107,088 (2), which showed potent anticancer activity. A beta-D-ribofuranoside, J-109,534 (3), was found to be 6 times more potent than J-107,088 at inhibiting topoisomerase I.

  在葡萄糖基团上修饰的新吲哚并咔唑化合物NB-506（1）产生了β-D-吡喃葡萄糖苷J-107,088（2），该化合物具有强大的抗癌活性。发现β-D-核呋喃糖苷J-109,534（3）在抑制拓扑异构酶I方面的效力是J-107,088的6倍。
• Synthesis and biological activities of NB-506 analogues: Effects of the positions of two hydroxyl groups at the indole rings
  作者：Mitsuru Ohkubo、Teruyuki Nishimura、Teruki Honma、Ikuko Nishimura、Satoru Ito、Tomoko Yoshinari、Hiroharu Arakawa、Hiroyuki Suda、Hajime Morishima、Susumu Nishimura

  DOI：10.1016/s0960-894x(99)00595-8

  日期：1999.12

  course of a study of 6-N-amino-substituted analogues of NB-506 (1), a more potent anticancer drug, J-109,404 (2), in which the formyl group of NB-506 was replaced with a 1,3-dihydroxypropane group, was reported. A study of further modification in the positions of two hydroxyl groups at the indole rings of 2 resulted in the discovery of a 2,10-dihydroxy analogue, J-107,088 (3), which is a promising anticancer

  在研究NB-506的6-N-氨基取代类似物的过程中，一种更有效的抗癌药物J-109,404（2），其中NB-506的甲酰基被1取代。报道了3-3-二羟基丙烷基团。进一步研究吲哚环2上两个羟基位置的进一步修饰，发现了2,10-二羟基类似物J-107,088（3），这是一种有前途的抗癌药物，其治疗范围比J-109404。
• NOVEL INDOLOPYRROLOCARBAZOLE DERIVATIVE WITH ANTITUMOR ACTIVITY
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1666485A1

  公开（公告）日：2006-06-07

  The present invention relates to a novel indolopyrrolocarbazole derivative which is represented by the formula [I]: wherein: A represents O, NH, or CH2; R1 represents a single bond, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, etc.; R2 represents a phenyl group, a naphthyl group, or a five- or six-membered aromatic or aliphatic heterocyclic ring having at least one atom selected from N, S, or O, wherein the phenyl group, naphthyl group, aromatic or aliphatic heterocyclic ring may be substituted; and G represents a hexose group or a pentose group, or a pharmaceutically acceptable salt thereof

  本发明涉及一种新颖的吲哚吡咯咯嗪衍生物，其由以下式[I]表示：其中：A代表O、NH或CH2；R1代表单键、较低的烷基、较低的烯基、较低的炔基等；R2代表苯基、萘基或含有N、S或O中至少一个原子的五元或六元芳香或脂环，其中苯基、萘基、芳香或脂环可以被取代；G代表己糖基或戊糖基，或其药用可接受的盐。
• Indolopyrrolocarbazole derivatives and antitumor agents
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US06703373B1

  公开（公告）日：2004-03-09

  A compound represented by the formula or a pharmaceutically acceptable salt thereof wherein R represents an unsubstituted pyridyl, furyl or thienyl group, or a pyridyl, furyl or thienyl group each of which has one or more substituents selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group except that when the pyridyl, furyl or thienyl group has a lower alkoxy group as a substituent, each of which simultaneously has another substituent selected from the group consisting of a hydroxyl group, a lower alkoxy group, a hydroxy lower alkyl group and a hydroxy lower alkenyl group, m represents an integer of 1 to 3, and G represents a &bgr;-D-glucopyranosyl group, and the positions of substitution of the hydroxyl groups on the indolopyrrolocarbazole ring are the 1- and 11-positions, or the 2- and 10-positions, and an antitumore agent containing it as an effective ingredient. The compounds have a better antitumor action than known compounds having a similar structure.

  化合物的化学式为或其药学上可接受的盐，其中R代表未取代的吡啶基，呋喃基或噻吩基，或者是带有一个或多个取代基的吡啶基，呋喃基或噻吩基，所述取代基选自羟基，较低的烷氧基，羟基较低的烷基基团和羟基较低的烯基基团的群，但是当吡啶基，呋喃基或噻吩基带有较低的烷氧基取代基时，每个取代基同时具有羟基，较低的烷氧基，羟基较低的烷基基团和羟基较低的烯基基团中的另一个取代基时，m表示1到3的整数，G表示β-D-葡萄糖吡喃糖基，并且羟基取代在吲哚吡咯喹啉环上的位置为1-和11-位置，或2-和10-位置，以及含有其作为有效成分的抗肿瘤剂。这些化合物比具有类似结构的已知化合物具有更好的抗肿瘤作用。
• Parenteral formulation and thermal degradation pathways of a potent rebeccamycin based indolocarbazole topoisomerase I inhibitor
  作者：Yuichi Sato、David Breslin、Hideyuki Kitada、Wataru Minagawa、Takashi Nomoto、Xue-Zhi Qin、Shyam B. Karki

  DOI：10.1016/j.ijpharm.2010.01.004

  日期：2010.5

  were determined by relative kinetics and degradation product identification using LC/MS, LC/MS/MS, and NMR analysis. The primary mode of degradation of 1 in this aqueous cosolvent formulation is hydrolysis affording the anhydride 2 (in equilibrium with the dicarboxylic acid 3) and release of the hydrazine diol side chain 11. Subsequent oxidative degradation of 11 occurs in several chemical steps which

  描述了实用的和药学上可接受的肠胃外剂型1的开发。选择了一种助溶剂制剂策略，以实现通过静脉输液给药所需的1人剂量。为商业开发和II期临床供应选择的1的最终市场配方是将拓扑异构酶抑制剂溶解在50％丙二醇水溶液中的载体，其中50mM柠檬酸盐缓冲至pH 4。使用LC / MS，LC / MS / MS和NMR分析通过相对动力学和降解产物鉴定确定3-5的pH范围。